Propelled by advances in molecular biology, the treatment of colorectal cancer is on the verge of dramatic change and a promising future as innovative vaccines will replace chemotherapy.

Antigenics Inc. (NASDAQ: AGEN) reported results for the quarter ended September 30, 2008.

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.

Antigenics Inc. (NASDAQ: AGEN) today announced that Garo Armen, Ph.D., the company's chairman and chief executive officer, will present at the Rodman and Renshaw 10th Annual Healthcare Conference at the Palace Hotel in New York on Monday, November 10, 2008 at 12:25 p.m. Eastern Time. Dr.

Antigenics, a biotechnology company, has submitted a marketing authorization application to the European Medicines Agency requesting approval for Oncophage in earlier-stage, localized renal cell carcinoma under the conditional authorization provision.